Drug
sarcosine
sarcosine is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
4
80%
Ph not_applicable
1
20%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (80.0%)
N/A1 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia
NCT01503359
completedphase_2
Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia
NCT01047592
completednot_applicable
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
NCT00538070
completedphase_2
N-methylglycine (Sarcosine) Treatment for Depression
NCT00977353
completedphase_2
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
NCT00328276
Clinical Trials (5)
Showing 5 of 5 trials
NCT01503359Phase 2
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia
NCT01047592Phase 2
Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia
NCT00538070Not Applicable
A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
NCT00977353Phase 2
N-methylglycine (Sarcosine) Treatment for Depression
NCT00328276Phase 2
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5